Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 8-9, Août–Septembre 2011
Page(s) 733 - 736
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011278015
Publié en ligne 31 août 2011
  1. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 2007 ; 8 : 101-112. [CrossRef] [PubMed]
  2. Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 2010 ; 13 : 812-818. [CrossRef] [PubMed]
  3. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 2002 ; 298 : 789-791. [CrossRef] [PubMed]
  4. Small DH, Mok SS, Bornstein JC. Alzheimer’s disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2001 ; 2 : 595-598. [CrossRef] [PubMed]
  5. Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer’s disease. Mol Neurobiol 2008 ; 37 : 73-82. [CrossRef] [PubMed]
  6. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000 ; 113 : 1857-1870. [PubMed]
  7. McGowan E, Pickford F, Kim J, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005 ; 47 : 191-199. [CrossRef] [PubMed]
  8. Marcello E, Epis R, Di Luca M. Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer’s disease pathogenesis. Eur J Pharmacol 2008 ; 585 : 109-118. [CrossRef] [PubMed]
  9. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 2006 ; 1 : 5. [CrossRef] [PubMed]
  10. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008 ; 283 : 29615-29619. [CrossRef] [PubMed]
  11. Ghosal K, Vogt DL, Liang M, et al. Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 2009 ; 106 : 18367-18372. [CrossRef]
  12. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002 ; 416 : 535-539. [CrossRef] [PubMed]
  13. Ashe KH, Zahs KR. Probing the biology of Alzheimer’s disease in mice. Neuron 2010 ; 66 : 631-645. [CrossRef] [PubMed]
  14. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996 ; 274 : 99-102. [CrossRef] [PubMed]
  15. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006 ; 440 : 352-357. [CrossRef] [PubMed]
  16. Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010 ; 107 : 2295-2300. [CrossRef]
  17. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008 ; 14 : 837-842. [CrossRef] [PubMed]
  18. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 2004 ; 44 : 181-193. [CrossRef] [PubMed]
  19. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat Rev Neurol 2010 ; 6 : 108-119. [CrossRef] [PubMed]
  20. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999 ; 2 : 271-276. [CrossRef] [PubMed]
  21. Gureviciene I, Ikonen S, Gurevicius K, et al. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. Neurobiol Dis 2004 ; 15 : 188-195. [CrossRef] [PubMed]
  22. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci USA 1999 ; 96 : 3228-3233. [CrossRef]
  23. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009 ; 66 : 435-440. [CrossRef] [PubMed]
  24. Chang EH, Savage MJ, Flood DG, et al. AMPA receptor downscaling at the onset of Alzheimer’s disease pathology in double knockin mice. Proc Natl Acad Sci USA 2006 ; 103 : 3410-3415. [CrossRef]
  25. Hsieh H, Boehm J, Sato C, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006 ; 52 : 831-843. [CrossRef] [PubMed]
  26. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005 ; 8 : 1051-1058. [CrossRef] [PubMed]
  27. Li S, Hong S, Shepardson NE, et al. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009 ; 62 : 788-801. [CrossRef] [PubMed]
  28. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 2007 ; 27 : 796-807. [CrossRef] [PubMed]
  29. Wang HY, Lee DH, D’Andrea MR, et al. Beta-Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem 2000; 275 : 5626-32. [CrossRef] [PubMed]
  30. Gasparini L, Dityatev A. Beta-amyloid and glutamate receptors. Exp Neurol 2008 ; 212 : 1-4. [CrossRef] [PubMed]
  31. Renner M, Lacor PN, Velasco PT, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010 ; 66 : 739-754. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.